+

PE20071095A1 - Derivados policiclicos de indazol como inhibidores de erk - Google Patents

Derivados policiclicos de indazol como inhibidores de erk

Info

Publication number
PE20071095A1
PE20071095A1 PE2006001592A PE2006001592A PE20071095A1 PE 20071095 A1 PE20071095 A1 PE 20071095A1 PE 2006001592 A PE2006001592 A PE 2006001592A PE 2006001592 A PE2006001592 A PE 2006001592A PE 20071095 A1 PE20071095 A1 PE 20071095A1
Authority
PE
Peru
Prior art keywords
alkyl
indazol
phenyl
erk
inhibitors
Prior art date
Application number
PE2006001592A
Other languages
English (en)
Inventor
Alan Cooper
Yongqi Deng
Shipps
Neng-Yang Shih
Hugh Zhu
Robert Sun
Joseph M Kelly
Ronald Doll
Yang Nan
Tong Wang
Jagdish Desai
James J-S Wang
Youhao Dong
Vincent Madison
Li Xiao
Alan W Hruza
M Arshad Siddiqui
Ahmed A Samatar
Sunil Paliwal
Hon-Chung Tsui
Azim A Celebi
Yiji Wu
Sobhana Babu Boga
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20071095A1 publication Critical patent/PE20071095A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A DERIVADOS POLICICLICOS DE INDAZOL DE FORMULA (1.0), EN DONDE Y1, Y2, Y3 SON INDEPENDIENTEMENTE -CH=, -N= y -CR9=; Z ES 1 A 3; Q ES a), b) ENTRE OTROS; R1 ES -CN, -NH2,-OR10, R10, C(O)R10, -(C(R30)2)n-NR32-C(O)-R10, ENTRE OTROS; R3, R4, R5, R6 Y R7 SON INDEPENDIENTEMENTE H, ALQUENILO, ALQUILO, ENTRE OTROS; R8 ES H, OH, ALQUILO, ENTRE OTROS; R9 ES HALOGENO, CN, NH2, ENTRE OTROS; R35 ES H O ALQUILO(C1-C6); R36 ES H, ALQUILO O -O-ALQUILO. SON SELECCIONADOS: [3-(4-FLUOR-FENIL)-1H-INDAZOL-5-IL]-AMIDA DE ACIDO 3-AMINO-1-{2-OXO-2-[4-(4-PIRIDIN-2-IL-FENIL)-PIPERAZIN-1-IL]-ETIL}-PIRROLIDIN-3-CARBOXILICO, [3-(4-FLUOR-FENIL)-1H-INDAZOL-5-IL]-AMIDA DE ACIDO 3-FORMILAMINO-1-(2-METIL-4-[4-(5-METIL-PIRIMIDIN-2-IL)-FENIL]-PIPERAZIN-1-IL}-2-OXO-ETIL)-PIRROLIDIN-3-CARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE ERK, POR LO QUE SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2006001592A 2005-12-13 2006-12-12 Derivados policiclicos de indazol como inhibidores de erk PE20071095A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74985605P 2005-12-13 2005-12-13

Publications (1)

Publication Number Publication Date
PE20071095A1 true PE20071095A1 (es) 2007-11-19

Family

ID=37969564

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2010000279A PE20100562A1 (es) 2005-12-13 2006-12-12 Derivados policiclicos de indazol como inhibidores de erk
PE2006001592A PE20071095A1 (es) 2005-12-13 2006-12-12 Derivados policiclicos de indazol como inhibidores de erk

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2010000279A PE20100562A1 (es) 2005-12-13 2006-12-12 Derivados policiclicos de indazol como inhibidores de erk

Country Status (29)

Country Link
US (1) US20070191604A1 (es)
EP (1) EP1966151B1 (es)
JP (1) JP4881957B2 (es)
KR (1) KR101417136B1 (es)
CN (1) CN101370784B (es)
AR (1) AR056891A1 (es)
AT (1) ATE527240T1 (es)
AU (1) AU2006326616B2 (es)
BR (1) BRPI0619823B8 (es)
CA (1) CA2633023C (es)
CY (1) CY1112760T1 (es)
DK (1) DK1966151T3 (es)
EC (1) ECSP088550A (es)
ES (1) ES2372976T3 (es)
HK (1) HK1114851A1 (es)
HR (1) HRP20110892T1 (es)
IL (1) IL192034A (es)
MY (1) MY149430A (es)
NO (1) NO341831B1 (es)
NZ (1) NZ569087A (es)
PE (2) PE20100562A1 (es)
PL (1) PL1966151T3 (es)
PT (1) PT1966151E (es)
RS (1) RS51981B (es)
RU (1) RU2442778C9 (es)
SI (1) SI1966151T1 (es)
TW (1) TWI344466B (es)
WO (1) WO2007070398A1 (es)
ZA (1) ZA200805525B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
AU2007218059A1 (en) * 2006-02-16 2007-08-30 Schering Corporation Pyrrolidine derivatives as ERK inhibitors
JP2009542666A (ja) 2006-06-30 2009-12-03 シェーリング コーポレイション Ｐ５３活性を増加させる置換ピペリジンおよびその使用
PE20090326A1 (es) * 2007-06-05 2009-04-04 Schering Corp Compuestos heterociclos como inhibidores de erk
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
WO2009073513A1 (en) * 2007-11-30 2009-06-11 Schering Corporation Braf biomarkers
CA2714479A1 (en) * 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
JP2011513331A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
US20110278332A1 (en) * 2009-03-26 2011-11-17 Protexer, Inc. Shoe cover removal apparatus
WO2009137649A2 (en) * 2008-05-07 2009-11-12 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer
US8586543B2 (en) * 2008-08-19 2013-11-19 Merck Sharp & Dohme Corp. IL-8 biomarker for monitoring cancer treatment with certain ERK inhibitors
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
US8609675B2 (en) 2009-07-02 2013-12-17 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds as novel mTOR inhibitors
AU2010300925A1 (en) * 2009-09-30 2012-03-29 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
EA023838B1 (ru) 2009-10-14 2016-07-29 Мерк Шарп Энд Домэ Корп. ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ
WO2011123937A1 (en) * 2010-04-06 2011-10-13 University Health Network Kinase inhibitors and method of treating cancer with same
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2649065A1 (en) * 2010-12-09 2013-10-16 Amgen Inc. Bicyclic compounds as pim inhibitors
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CA2830780A1 (en) 2011-03-22 2012-09-27 Amgen Inc. Azole compounds as pim inhibitors
US20140045832A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Insulin-Like Growth Factor-1 Receptor Inhibitors
EP2736338B1 (en) 2011-07-26 2019-01-23 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS
WO2013062923A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2013096150A1 (en) 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
ITMI20120135A1 (it) * 2012-02-02 2013-08-03 Diab Int Ab Procedimento per la produzione di schiume di pet e schiume di pet ottenute con questo procedimento
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN103450163B (zh) * 2012-05-29 2017-06-23 中国医学科学院药物研究所 吲唑类化合物、其制备方法及其药物用途
MX2015003535A (es) 2012-09-19 2015-07-14 Novartis Ag Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.
JP6280554B2 (ja) * 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
HUE039306T2 (hu) 2013-11-01 2018-12-28 Novartis Ag Kináz inhibitor aminoheteroaril-benzamidok
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
WO2016095089A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095088A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
EP3355923B1 (en) 2015-10-01 2022-02-23 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma
CA3001799A1 (en) 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
WO2017099591A1 (en) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment of inhibitor resistant braf-mutant cancers
WO2017156495A1 (en) * 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating bruton's tyrosine kinase
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition
CA3037064A1 (en) 2016-10-05 2018-04-12 Zeno Royalties & Milestones, LLC Spirocyclic compounds
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
WO2019178079A1 (en) 2018-03-12 2019-09-19 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
CN114605329B (zh) * 2022-03-28 2024-01-26 河南中医药大学 取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
EP1200422A2 (en) * 2000-02-05 2002-05-02 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
EP1537087B1 (fr) * 2002-09-05 2012-11-28 Aventis Pharma S.A. Derives de 3-aminoindazole comme inhibiteurs de kinase et compositions pharmaceutiques les renfermant

Also Published As

Publication number Publication date
PE20100562A1 (es) 2010-08-20
EP1966151A1 (en) 2008-09-10
RU2442778C9 (ru) 2012-08-10
KR20080085018A (ko) 2008-09-22
PL1966151T3 (pl) 2012-02-29
CY1112760T1 (el) 2016-02-10
CA2633023A1 (en) 2007-06-21
BRPI0619823B1 (pt) 2020-11-17
US20070191604A1 (en) 2007-08-16
BRPI0619823B8 (pt) 2021-05-25
CN101370784B (zh) 2012-10-10
ATE527240T1 (de) 2011-10-15
MY149430A (en) 2013-08-30
TWI344466B (en) 2011-07-01
TW200732324A (en) 2007-09-01
ZA200805525B (en) 2009-11-25
ES2372976T3 (es) 2012-01-30
HRP20110892T1 (hr) 2011-12-31
KR101417136B1 (ko) 2014-08-07
ECSP088550A (es) 2008-07-30
DK1966151T3 (da) 2012-01-30
AU2006326616B2 (en) 2012-09-06
IL192034A0 (en) 2008-12-29
EP1966151B1 (en) 2011-10-05
BRPI0619823A8 (pt) 2019-01-22
JP4881957B2 (ja) 2012-02-22
CA2633023C (en) 2015-11-24
RS51981B (en) 2012-02-29
PT1966151E (pt) 2011-12-20
NZ569087A (en) 2011-09-30
IL192034A (en) 2014-08-31
BRPI0619823A2 (pt) 2011-11-08
WO2007070398A1 (en) 2007-06-21
JP2009519338A (ja) 2009-05-14
RU2442778C2 (ru) 2012-02-20
NO20083114L (no) 2008-09-12
HK1114851A1 (en) 2008-11-14
SI1966151T1 (sl) 2012-02-29
CN101370784A (zh) 2009-02-18
NO341831B1 (no) 2018-01-29
RU2008128119A (ru) 2010-01-20
AU2006326616A1 (en) 2007-06-21
AR056891A1 (es) 2007-10-31

Similar Documents

Publication Publication Date Title
PE20071095A1 (es) Derivados policiclicos de indazol como inhibidores de erk
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
NO20090328L (no) Nye forbindelser 385
EA200900658A1 (ru) Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами
PE20090326A1 (es) Compuestos heterociclos como inhibidores de erk
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
TW200745111A (en) New compounds
MY146662A (en) Novel n-(8-heteroaryltetrahydronaphtalene-2yl) or n-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
PE20060857A1 (es) Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
NO20090760L (no) Nye tricykliske spiropiperidinforbindelser, deres synteser og deres anvendelser som modulatorer av kemokinreseptor-aktivitet
PE20140609A1 (es) Diazacarbazoles y metodos de uso
PE20091623A1 (es) DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
NO20082496L (no) Pyrazinderivater
MY162022A (en) Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors
NO20090327L (no) Nye forbindelser 384
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
ATE507212T1 (de) Morpholine als 5ht2c-agonisten
PE20061316A1 (es) Derivados de pirazol como antagonistas del receptor de progesterona

Legal Events

Date Code Title Description
FG Grant, registration
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载